A method for providing granulocytopoietic therapy to a mammal comprising administering an effective amount of a hpG-CSF polypeptide having an amino acid sequence selected from the group consisting of: +1 +10 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro +20 Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln +30 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala +40 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys +50 Leu Cys His Pro Glu Glu Leu Val Leu Leu +60 Gly His Ser Leu Gly Ile Pro Trp Ala Pro +70 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln +80 Leu Ala Gly Cys Leu Ser Gln Leu His Ser +90 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln +100 Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly +110 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val +120 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln +130 Met Glu Glu Leu Gly Met Ala Pro Ala Leu +140 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe +150 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly +160 Val Leu Val Ala Ser His Leu Gln Ser Phe +170 Leu Glu Val Ser Tyr Arg Val Leu Arg His +174 Leu Ala Gln Pro; and -1 +1 +10 Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro +20 Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln +30 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala +40 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys +50 Leu Cys His Pro Glu Glu Leu Val Leu Leu +60 Gly His Ser Leu Gly Ile Pro Trp Ala Pro +70 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln +80 Leu Ala Gly Cys Leu Ser Gln Leu His Ser +90 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln +100 Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly +110 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val +120 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln +130 Met Glu Glu Leu Gly Met Ala Pro Ala Leu +140 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe +150 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly +160 Val Leu Val Ala Ser His Leu Gln Ser Phe +170 Leu Glu Val Ser Tyr Arg Val Leu Arg His +174 Leu Ala Gln Pro; __________________________________________________________________________ __________________________________________________________________________ and analogs thereof wherein one or more cysteines residues located at positions 17, 36, 42, 64 and 74 are replaced by serine. view more

A method of claim 2 wherein said therapy is in conjunction with chemotherapy.

A method of claim 2 wherein said therapy is in conjunction with radiation therapy.

A method of claim 2 wherein said therapy is in conjunction with removal of blood progenitor cells.

An isolated human pluripotent granulocyte colony stimulating factor (hpG-CSF) polypeptide having an amino acid sequence selected from the group consisting of: ##STR25## ##STR26## ##STR27## ##STR28## ##STR29## ##STR30## ##STR31## ##STR32## ##STR33## ##STR34## ##STR35## ##STR36## ##STR37## ##STR38## ##STR39## ##STR40## ##STR41## ##STR42## and ##STR43## ##STR44## ##STR45## ##STR46## ##STR47## ##STR48## ##STR49## ##STR50## ##STR51## ##STR52## ##STR53## ##STR54## ##STR55## ##STR56## ##STR57## ##STR58## ##STR59## ##STR60## ______________________________________ ______________________________________ and analogs thereof wherein one or more cysteines residues located at positions 17, 36, 42, 64 and 74 are replaced by serine. view more

A composition comprising the hpG-CSF polypeptide of claim 1 and a carrier.